This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

David J. Conti, MD; Brian M. Freed, PhD; T. Paul Singh, MD; Michael Gallichio, MD; Scott A. Gruber, MD, PhD; Neil Lempert, MD

Arch Surg. 1995;130(11):1217-1222.

Abstract
Objective
To evaluate the efficacy, safety, and cost of preemptive ganciclovir therapy in cytomegalovirus (CMV)-seropositive renal transplant recipients treated with antilymphocyte antibody (ALA) preparations.

Design and Setting
A prospective, randomized trial at a 650-bed tertiary medical center hospital.

Patients
Forty consecutive CMV-seropositive renal allograft recipients who underwent transplantation between January 1992 and January 1994 and were treated with ALA for induction immunosuppression or acute rejection therapy.

Main Outcome Measures
The incidence and severity of CMV disease, length of hospitalization, and patient and allograft survival.

Intervention
Cytomegalovirus infection prophylaxis by use of intravenous ganciclovir during ALA therapy was administered to 22 patients (group 1) and the results were compared with those obtained in 18 control patients who did not receive prophylaxis for CMV disease (group 2).

Results
Preemptive ganciclovir therapy significantly reduced the incidence of CMV disease (P<.05) in CMV-seropositive renal transplant patients who were treated with ALA and was well tolerated. In addition, the cost of prophylactic therapy was offset by the decreased length of hospitalization observed in patients in group 1.

Conclusion
Preemptive ganciclovir therapy provides a cost-effective approach toward significantly improving the outcome of renal transplantation in CMV-seropositive patients treated with ALA.

(Arch Surg. 1995;130:1217-1222)

Author Affiliations
From the Department of Surgery, Section of Transplantation, Albany Medical College, Albany, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients
Kalil and Stoner
ANN INTERN MED 2006;144:457-457.
FULL TEXT  

Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
Singh and Wagener
ANN INTERN MED 2006;144:456-457.
FULL TEXT  

Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients
Kalil et al.
ANN INTERN MED 2005;143:870-880.
ABSTRACT | FULL TEXT  

Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy
Wang et al.
Ann. Thorac. Surg. 2004;78:267-272.
ABSTRACT | FULL TEXT  

Distinguishing Cytomegalovirus (CMV) Infection and Disease with CMV Nucleic Acid Assays
Caliendo et al.
J. Clin. Microbiol. 2002;40:1581-1586.
ABSTRACT | FULL TEXT  

Management of herpes virus infections following transplantation
J Antimicrob Chemother 2000;45:729-748.
FULL TEXT  

New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients
Sia and Patel
Clin. Microbiol. Rev. 2000;13:83-121.
ABSTRACT | FULL TEXT  

Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation
Lowance et al.
NEJM 1999;340:1462-1470.
ABSTRACT | FULL TEXT